Companies › AVXL

Anavex Life Sciences (AVXL)

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001314052 · EDGAR filings · Updated 2026-07-24

Anavex Life Sciences (AVXL) has reported institutional ownership of 44.4%, with 188 institutional managers holding positions valued at $121.8M per the latest 13F reporting period. SEC filings include an active notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01).

Filings this week (1)

• 2026-07-24 — PREC14A filed

Every filing links to the official SEC document. Real-time filing alerts for this company are available inside the app.

Latest updates

• 2026-07-20 — Current report (8-K) filed
• 2026-06-26 — Current report (8-K) filed
• 2026-05-22 — Current report (8-K) filed
• 2026-05-15 — Current report (8-K) filed
• 2026-05-14 — Initial insider ownership filed (Form 3)

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, Anavex Life Sciences has 188 institutional holders and institutional ownership of 44.4%.

Insider activity

Insiders reported 4 transactions (0 buys, 0 sells) across 2 reporting insiders, with a net reported value of $0.

Data flags from SEC filings

Related companies

HERON THERAPEUTICS INC (HRTX) · MACROGENICS INC (MGNX) · CRONOS GROUP INC (CRON) · NKARTA INC (NKTX) · CORBUS PHARMACEUTICALS HLDGS (CRBP) · Whitehawk Therapeutics Inc (WHWK)